Healthcare
Healios K.K.(HLOSF)
Live Price
Offline$1.80
+0.00% today
1Y Change
-43.22%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $35.42B
- Revenue Growth
- -81.4%
- EPS Growth
- +57.4%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Healios K.K. (HLOSF) is a Healthcare stock with a market cap of $35.42B and listed on OTC. The stock last traded around $1.80 and down 43.2% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -81.4%, EPS growth of +57.4%, a dividend yield of 0.0%. What stands out right now is revenue -81.4%, EPS +57.4%, free cash flow -57.1% with operating margin -3272.1% and ROIC -23.6%. Valuation already assumes a fairly strong business story at price/sales 340.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HLOSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-81.4% vs +7.6% peer median
Operating Margin
Below sector median
-3272.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -81.4% and EPS is at +57.4%, with operating margin around -3272.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | +0.0% | +0.0% | -18.2% |
2026 Feb 16, 2026 | +306.5% | +0.0% | +0.0% | +31.0% |
2025 Sep 30, 2025 | -23.4% | +0.0% | +0.0% | -15.7% |
Benchmark Edge
HLOSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HLOSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HLOSF Max Drawdown
-59.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HLOSF and SPY.
Company Overview
Healios K.K.
Other OTC
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
- Leadership
- Tadahisa S. Kagimoto
- IPO Date
- Nov 9, 2020
- Employees
- 65
- Street Address
- Yurakucho Denki Building
- Mailing
- Tokyo, 100-0006
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- +81 3 6268 0284
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 340.6
- Price/Book
- 6.9
Growth
- Revenue
- -81.4%
- EPS
- +57.4%
- Free Cash Flow
- -57.1%
Profitability
- Gross Margin
- -374.0%
- Operating Margin
- -3272.1%
- Net Margin
- -2131.7%
- ROE
- -80.4%
- ROIC
- -23.6%
Balance Sheet
- Debt/Equity
- 0.53
- Current Ratio
- 2.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.